Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded CB-NK cells and cetuximab in colorectal cancer with minimal residual disease
NCT05040568Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Jan 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cord blood-derived expanded allogeneic natural killer cells in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Activity of the CB-NK infusion in combination with cetuximab (ctDNA clearance) at 1 year. Started Feb 2022; status: completed.
02
Drugs
cord blood-derived expanded allogeneic natural killer cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05040568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040568.